| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Purity | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
ODN 2088 is a potent inhibitor of TLR3, TLR7, and TLR9. It shows no cytotoxicity and inhibits the release of IFN-α and IL-6[1][2][3]. It is supplied as a white to off-white solid (MW 4878.00) at 98.82% purity.
Physical & Chemical Properties
| CAS Number | 1146541-45-8 |
|---|---|
| Molecular Weight | 4878.00 g/mol |
| Purity | 98.82% |
| Appearance | Solid |
| Color | White to off-white |
| Sequence | DNA, d(P-thio)(T-C-C-T-G-G-C-G-G-G-G-A-A-G-T) |
| Signaling Pathway | Immunology/Inflammation |
| Storage | -20°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
ODN 2088 (0.01-10 μM; 48 h) is not cytotoxic to human PBMCs[1]. ODN 2088 (0.01-10 μM; 24 h) inhibits IFN-α release from human PBMCs stimulated with CpG-ODN 2216 (3 μM) and the TLR7-ligand RNA-ORN 22075 (5 μM)[1]. In human PBMCs, ODN 2088 (0.01-10 μM; 48 h) barely inhibits IL-6 release stimulated with CpG-ODN 2006 (100 nM) but does inhibit IL-6 release stimulated with Imiquimod (5 μg/ml)[1]. ODN 2088 (0.1-10 μM; 24 h) barely inhibits IL-6 release from B-cells stimulated with CpG-DNA 2006 (100 nM) but inhibits IL-6 release from human B-cells stimulated with Imiquimod (5 μg/ml)[1]. ODN 2088 presumably impairs the TLR9-induced signaling triggered by CpG-ODNs through competitive binding to the C-terminal fragment of TLR9[1]. In BMDMs stimulated with CpG-ODN 1826 (100 nM), ODN 2088 (0.001-10 μM; 24 h) inhibits TNF-α secretion in a dose-dependent manner, and it shows only weak inhibition when the cells are stimulated with the TLR7-agonist imiquimod[3]. ODN 2088 (10 μM) stimulates B cell proliferation[3].
Cell Cytotoxicity Assay[1]
| Cell Line | Human PBMCs |
|---|---|
| Concentration | 0.01, 0.1, 1, 10 μM |
| Incubation Time | 48 h |
| Result | Showed no cytotoxic for for human PBMCs. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Hepatocyte-derived extracellular vesicles carrying damaged mitochondria drive neutrophil extracellular traps formation and exacerbate acetaminophen-induced liver injury. Int Immunopharmacol 2026 Jan 15:169:115944. PMID: 41349466
AQP4-IgG-Induced Astrocyte-Derived Small Extracellular Vesicles Carrying Mitochondrial DNA Regulate the TLR9/MyD88/NF-κB Pathway to Drive Microglial Activation and Neuromyelitis Optica. Neurochem Res 2026 Feb 11;51(1):73. PMID: 41670763
TLR9/MyD88/NF-κB signaling mediates mental stress-induced exacerbation of psoriasis through immune dysregulation in a mouse model. PLoS One 2026 Mar 6;21(3):e0344474. PMID: 41790734
Arch Dermatol Res. 2026 Jul 11;318(1):245.
